There is no conflict of interest of any anthors in relation to this submission.
Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing–remitting multiple sclerosis
Version of Record online: 23 JUN 2009
© 2009 British Society for Immunology
Clinical & Experimental Immunology
Volume 158, Issue 1, pages 26–30, October 2009
How to Cite
Xu, L., Xu, Z. and Xu, M. (2009), Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing–remitting multiple sclerosis. Clinical & Experimental Immunology, 158: 26–30. doi: 10.1111/j.1365-2249.2009.03987.x
- Issue online: 2 SEP 2009
- Version of Record online: 23 JUN 2009
- Accepted for publication 11 June 2009
- 1Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 2001; 1:257–62., .
- 2The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008; 4:384–98., .
- 3Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8:913–19., .
- 4Decreased 4-1BB expression on CD4+CD25(high) regulatory T cells in peripheral blood of patients with multiple sclerosis. Clin Exp Immunol 2008; 154:22–9., , , , .
- 5Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007; 179:1322–30., , et al.
- 6Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007; 147:412–18., , , , , .
- 7Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83:1432–46., , et al.
- 8Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. J Neurol Sci 2006; 251:91–7., , , , , .
- 9Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971–9., , , .
- 10Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35:3343–52., , et al.
- 11Multiple sclerosis and regulatory cells. Nippon Rinsho 2005; 63 (Suppl. 5):422–6., , .
- 12Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing–remitting multiple sclerosis. J Neuroimmunol 2007; 182:204–11., , et al.
- 13Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol 2007; 124:284–93., , et al.
- 14Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neurol 1993; 33:10–17., , , , , .
- 15Revision of McDonald's new diagnostic criteria for multiple sclerosis. Nervenarzt 2006; 77:7–45., , , , , .
- 16Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol 2007; 178:3400–8., , , , .
- 17Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. J Neuroimmunol 2006; 176:153–61., , et al.